Expert panelists discuss the essential role of primary care in early skin cancer detection, balancing clinical judgment with emerging AI artificial intelligence tools, and more.

Solriamfetol's significant cognitive benefits may be the result of mechanisms operating independently of its wake-promoting effects, study authors suggest.

RAD 2025: Glick spoke to Patient Care about the similarities between TSW and a flare of atopic dermatitis as well as specific signs now being identified d as characteristic.

The phase 4 EVEREST study showed statistically significant improvements in polyp size reduction and smell identification ability as early as 4 weeks of treatment.

The American College of Lifestyle Medicine recently published "that guideline," and lead author Richard Rosenfeld, MD, MPH, MBA, says the timing was right.

Explore key insights from the 2025 Revolutionizing Atopic Dermatitis meeting, featuring expert interviews and the latest treatment advancements.

Authors say their findings support the accumulating evidence that late-life mood disorders may be a prodromal manifestation of dementia vs a risk factor alone.

Both oral and subcutaneous formulations of the long-acting GLP-1 and amylin receptor agonist move into stage 3 clinical trials following positive feedback from regulators.

mRNA1345 (mResvia) is now indicated for adults aged 18 to 59 years with underlying conditions including cardiovascular, respiratory, and endocrine disorders.

Your daily dose of the clinical news you may have missed.

At RAD 2025, pediatric dermatologist Elizabeth Swanson, MD, discussed the value of focused AD education and anticipated label expansions for several treatments.